TY  - GEN
AU  - Cho,L
AU  - Topol,E J
AU  - Balog,C
AU  - Foody,J M
AU  - Booth,J E
AU  - Cabot,C
AU  - Kleiman,N S
AU  - Tcheng,J E
AU  - Califf,R
AU  - Lincoff,A M
TI  - Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent
SN  - 0735-1097
PY  - 2000///0817
KW  - Abciximab
KW  - Aged
KW  - Angioplasty, Balloon, Coronary
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Female
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - Male
KW  - Middle Aged
KW  - Myocardial Infarction
KW  - drug therapy
KW  - Platelet Aggregation Inhibitors
KW  - Platelet Glycoprotein GPIIb-IIIa Complex
KW  - antagonists & inhibitors
KW  - Randomized Controlled Trials as Topic
KW  - Sex Factors
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/s0735-1097(00)00746-4
ER  -